跳至主要内容
临床试验/NCT00421278
NCT00421278已完成2 期

A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis

Merck Sharp & Dohme LLC0 个研究点目标入组 180 人开始时间: 2006年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
180
主要终点
To evaluate the effects of the drug, MK 0633, on an inflammatory marker in your blood that may affect the plaque in the arteries, know as atherosclerosis

研究概览

简要总结

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
40 Years 至 85 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease
  • Inflammatory marker found in your blood, known as hsCRP > 0.5 mg/L

排除标准

  • Age < 40 or > 85
  • Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
  • Liver diseased or abnormalities
  • HIV infection
  • Lupus, rheumatoid arthritis, cancer <5 years

研究组 & 干预措施

1

Experimental

Arm 1: Drug

干预措施: MK0633 (Drug)

结局指标

主要结局

To evaluate the effects of the drug, MK 0633, on an inflammatory marker in your blood that may affect the plaque in the arteries, know as atherosclerosis

时间窗: 4 Weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

The Effect of MK 0633 in Patients With... | 临床试验